9LB Stock Overview A clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Legend Biotech Corporation Competitors Price History & Performance
Summary of share price highs, lows and changes for Legend Biotech Historical stock prices Current Share Price US$32.60 52 Week High US$64.50 52 Week Low US$31.20 Beta 0.085 1 Month Change -16.41% 3 Month Change -20.49% 1 Year Change -39.63% 3 Year Change -24.19% 5 Year Change n/a Change since IPO 35.83%
Recent News & Updates
Legend Biotech Corporation Announces New Results from the Phase 3 CARTITUDE-4 Study Dec 10
Third quarter 2024 earnings released: US$0.68 loss per share (vs US$0.34 loss in 3Q 2023) Nov 14
Legend Biotech Corporation Appoints Alan Bash as President of CARVYKTI® Nov 05
New minor risk - Share price stability Sep 27
Legend Biotech Corporation, Annual General Meeting, Oct 21, 2024 Sep 23
Legend Biotech Achieves Breakthrough with Cilta-Cel Approval in China, Offering New Hope for Multiple Myeloma Patients Aug 28 See more updates
Legend Biotech Corporation Announces New Results from the Phase 3 CARTITUDE-4 Study Dec 10
Third quarter 2024 earnings released: US$0.68 loss per share (vs US$0.34 loss in 3Q 2023) Nov 14
Legend Biotech Corporation Appoints Alan Bash as President of CARVYKTI® Nov 05
New minor risk - Share price stability Sep 27
Legend Biotech Corporation, Annual General Meeting, Oct 21, 2024 Sep 23
Legend Biotech Achieves Breakthrough with Cilta-Cel Approval in China, Offering New Hope for Multiple Myeloma Patients Aug 28
Second quarter 2024 earnings released: US$0.10 loss per share (vs US$1.14 loss in 2Q 2023) Aug 11
Legend Biotech Corporation Appoints Peter Salovey as Independent Director, Effective August 9, 2024 Aug 09
Legend Biotech Corporation Announces Positive Overall Survival Results of Phase 3 CARTITUDE-4 Trial in Multiple Myeloma Jul 02
Legend Biotech Corporation Shares Data on the Earlier Use to Date of CARVYKTI in the Treatment of Multiple Myeloma and Important Subgroup Analyses At ASCO and EHA Jun 05
Legend Biotech Corporation to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA May 24
First quarter 2024 earnings released: US$0.32 loss per share (vs US$0.68 loss in 1Q 2023) May 13
Legend Biotech Corporation's CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma Apr 23
Legend Biotech Corporation Announces CARVYKTI (Ciltacabtagene Autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma Mar 16
Full year 2023 earnings released: US$2.94 loss per share (vs US$2.81 loss in FY 2022) Mar 12
Legend Biotech Provides Update on U.S. FDA and EMA Applications for Expanded Use of CARVYKTI® (ciltacabtagene autoleucel) in Earlier Lines of Treatment for Relapsed/Refractory Multiple Myeloma Jan 25
Legend Biotech Announces U.S. FDA Label Update for CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) Dec 22
Legend Biotech Corporation Announces Patient-Reported Outcome (Pro) Data from the Phase 3 CARTITUDE-4 Study Dec 12
Third quarter 2023 earnings released: US$0.34 loss per share (vs US$0.68 loss in 3Q 2022) Nov 21
Legend Biotech Corporation, Annual General Meeting, Sep 21, 2023 Aug 22
Second quarter 2023 earnings released: US$1.14 loss per share (vs US$1.25 loss in 2Q 2022) Aug 16
Legend Biotech Corporation Announces Submission of Supplemental Application to U.S. FDA for Expanded Use of CARVYKTI® (Ciltacabtagene Autoleucel) Jun 07
Legend Biotech Corporation Announces Results from the Phase 3 CARTITUDE-4 Study Jun 06
Legend Biotech Corporation Announces Submission to the European Medicines Agency for Expanded Use of CARVYKTI®? (Ciltacabtagene Autoleucel) May 26
First quarter 2023 earnings released: US$0.68 loss per share (vs US$0.27 loss in 1Q 2022) May 18
Legend Biotech Corporation to Demonstrate Progress in Advancing Potential Treatment Options for Patients with Multiple Myeloma at ASCO and EHA Annual Meetings May 17 Legend Biotech Corporation has completed a Follow-on Equity Offering in the amount of $350 million. May 10
Full year 2022 earnings released Mar 31
Second quarter 2022 earnings released: US$1.25 loss per share (vs US$0.66 loss in 2Q 2021) Feb 18 Legend Biotech Corporation Announces Research and Development Update
Legend Biotech Receives Notification of Delinquency from The Nasdaq Stock Market LLC Jan 10
Legend Biotech Announces Acceptance of Its New Drug Application for Ciltacabtagene Autoleucel (Cilta-Cel) in China Jan 03
Legend Biotech Corporation Announces FDA Clearance of IND Application for LB2102 in Extensive Stage Small Cell Lung Cancer Nov 22
High number of new and inexperienced directors Nov 16
Legend Biotech Corporation Shares Updated Data from Comprehensive Cilta-Cel Clinical Development Program at ASH 2022 Nov 04
Legend Biotech Corporation Elects Philip Yau as Director Oct 18
Legend Biotech Corporation Announces that CARVYKTI™ (ciltacabtagene autoleucel) Receives Approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma Sep 28
Legend Biotech Corporation, Annual General Meeting, Oct 14, 2022 Sep 17
Legend Biotech Corporation Provides Earnings Guidance for the Six Months Ended June 30, 2022 Aug 06
Legend Biotech Corporation Announces Board Changes Aug 05 Legend Biotech Corporation has completed a Follow-on Equity Offering in the amount of $350.02 million. Jul 29
Legend Biotech Corporation has completed a Follow-on Equity Offering in the amount of $350.02 million. Jul 28
First quarter 2022 earnings released: US$0.27 loss per share (vs US$0.61 loss in 1Q 2021) Jul 27
Legend Biotech Corporation Legend Biotech Announces Termination of Its Phase 1 Clinical Trial Under Investigational New Drug Application for LB1901 Jul 08
Longer-Term Data from CARTITUDE Program Continue to Show Deep and Durable Responses with Ciltacabtagene Autoleucel Across Lines of Therapy in Patients with Multiple Myeloma Jun 05
Legend Biotech Corporation Announces U.S. FDA Clearance of IND Application for Solid Tumor Car-T, Lb1908 for Relapsed or Refractory Gastric, Esophageal and Pancreatic Cancers Jun 04
First quarter 2022 earnings released: US$0.27 loss per share (vs US$0.61 loss in 1Q 2021) Jun 02
European Commission Grants Marketing Authorization to CARVYKTI of Legend Biotech Corporation May 27 Legend Biotech Appoints Lori Macomber as Chief Financial Officer May 10
High number of new and inexperienced directors Apr 27
Legend Biotech Announces Executive Changes Apr 04
Legend Biotech Corporation Announces Appointment of Guowei Fang as Global Head of Research and Early Development Apr 03
Full year 2021 earnings released: US$2.74 loss per share (vs US$2.57 loss in FY 2020) Apr 02
Legend Biotech Corporation's CARVYKTI™ (ciltacabtagene autoleucel), BCMA-Directed CAR-T Therapy, Receives U.S. FDA Approval for the Treatment of Adult Patients With Relapsed or Refractory Multiple Myeloma Mar 02
Legend Biotech Announces FDA Clinical Hold of Its Phase 1 Clinical Trial for LB1901 Feb 16
Forecast to breakeven in 2024 Jan 01
Legend Biotech Corporation has completed a Follow-on Equity Offering in the amount of $300 million. Dec 18
Third quarter 2021 earnings: EPS in line with analyst expectations despite revenue beat Dec 17
Legend Biotech Corporation Announces New and Updated Results from the Cartitude Clinical Development Program Studying Ciltacabtagene Autoleucel (Cilta-Cel) in the Treatment of Multiple Myeloma, Which Were Presented At the 63Rdamerican Society of Hematology (Ash) Annual Meeting and Exposition Dec 15
Legend Biotech Announces Submission of New Drug Application to Japanese Regulatory Authority for BCMA CAR-T Therapy Cilta-cel for the Treatment of Relapsed or Refractory Multiple Myeloma by Janssen Dec 07
No longer forecast to breakeven Nov 27
Third quarter 2021 earnings released: US$0.86 loss per share (vs US$0.50 loss in 3Q 2020) Nov 17
Forecast to breakeven in 2023 Oct 20
Forecast to breakeven in 2023 Sep 23
Legend Biotech Begins Phase 1 Clinical Trial in the US to Evaluate Investigational Anti-Cd4 Car-T Therapy for Relapsed or Refractory T-Cell Lymphoma Sep 14
Second quarter 2021 earnings released: US$0.66 loss per share (vs US$1.25 loss in 2Q 2020) Aug 25
Legend Biotech Announces New and Updated Data for Investigational BCMA CAR-T Ciltacabtagene Autoleucel for the Treatment of Relapsed or Refractory Multiple Myeloma at 2021 ASCO and EHA Meetings Jun 02
Genscript Biotech Corporation and Legend Biotech Corporation Announce New and Updated Results for Ciltacabtagene Autoleucel (cilta-cel), an Investigational BCMA-Directed CAR-T Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma to be Featured at the 2021 ASCO Annual Meeting and at the EHA Virtual Congress May 29
Legend Biotech Corporation Announces U.S. Food and Drug Administration Grants Bcma Car-T Cilta-Cel Priority Review for the Treatment for Relapsed/Refractory Multiple Myeloma May 27
Legend Biotech Corporation Announces EMA Acceptance of the MAA for Cilta-Cel for RRMM May 21
First quarter 2021 earnings released: US$0.61 loss per share (vs US$0.44 loss in 1Q 2020) May 18
Forecast to breakeven in 2024 May 18
Legend Biotech Corporation Reports New and Updated Data from BCMA CAR-T Program at 2021 ASCO and EHA Meetings May 13
Legend Biotech Announces Submission of European Marketing Authorisation Application for Bcma Car-T Therapy Ciltacabtagene Autoleucel (Cilta-Cel) for the Treatment of Relapsed And/Or Refractory Multiple Myeloma May 01
Full year 2020 earnings released: US$2.57 loss per share (vs US$1.33 loss in FY 2019) Apr 06
Full year 2020 earnings released: US$2.57 loss per share (vs US$1.33 loss in FY 2019) Mar 19
Legend Biotech Corporation to Report Q4, 2020 Results on Mar 18, 2021 Mar 11
New 90-day low: €20.00 Mar 05 Shareholder Returns 9LB DE Biotechs DE Market 7D -2.4% -2.9% -2.6% 1Y -39.6% -14.7% 6.9%
See full shareholder returns
Return vs Market: 9LB underperformed the German Market which returned 6.9% over the past year.
Price Volatility Is 9LB's price volatile compared to industry and market? 9LB volatility 9LB Average Weekly Movement 7.2% Biotechs Industry Average Movement 6.8% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.2% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 9LB's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 9LB's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel.
Show more Legend Biotech Corporation Fundamentals Summary How do Legend Biotech's earnings and revenue compare to its market cap? 9LB fundamental statistics Market cap €5.99b Earnings (TTM ) -€333.65m Revenue (TTM ) €498.54m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 9LB income statement (TTM ) Revenue US$520.18m Cost of Revenue US$607.90m Gross Profit -US$87.72m Other Expenses US$260.41m Earnings -US$348.13m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -1.90 Gross Margin -16.86% Net Profit Margin -66.92% Debt/Equity Ratio 26.6%
How did 9LB perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/22 21:00 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Legend Biotech Corporation is covered by 27 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Ishan Majumdar Baptista Research Huidong Wang Barclays Konstantinos Biliouris BMO Capital Markets Equity Research
Show 24 more analysts 